Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines.

We measured serum levels of circulating intercellular adhesion molecule-1 (cICAM-1) in patients with systemic sclerosis (SSc) and normal controls. The levels of cICAM-1 were determined by sandwich enzyme-linked immunosorbent assay in sera from 88 patients with SSc and in 20 healthy controls. In addition, these levels were examined in the supernatants of cultured peripheral blood mononuclear cells (PBMC) and dermal fibroblasts from 10 patients with SSc and 10 healthy control subjects. Serum levels of cICAM-1 were significantly higher in patients with SSc than in healthy controls. Serum cICAM-1 levels were significantly higher in patients with diffuse cutaneous SSc (dcSSc) than in patients with limited cutaneous SSc (lcSSc). These serum levels were correlated with the presence of contracture of phalanges, pulmonary fibrosis, joint involvement and increased erythrocyte sedimentation rate. The release of cICAM-1 was significantly increased in the supernatants of cultured PBMC from patients with SSc. Moreover, inflammatory cytokines (interferon-gamma, interleukin-1 and tumor necrosis factor-alpha) enhanced the release of cICAM-1 in vitro in SSc cells. These findings suggest that cICAM-1 may be involved in immune reactions in this disease.

[1]  C. Lovell,et al.  VCAM‐1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma , 1996, The British journal of dermatology.

[2]  C. Denton,et al.  Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. , 1995, British journal of rheumatology.

[3]  O. Hornstein,et al.  Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. , 1995, Arthritis and rheumatism.

[4]  X. Shi-wen,et al.  Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. , 1994, Arthritis and rheumatism.

[5]  M. Fujimoto,et al.  Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma. , 1994, Journal of the American Academy of Dermatology.

[6]  M. Fujimoto,et al.  Demonstration of interleukin 8 in serum samples of patients with localized scleroderma. , 1994, Archives of dermatology.

[7]  H. Ihn,et al.  Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. , 1994, Arthritis and rheumatism.

[8]  P. Lipsky,et al.  Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. , 1993, Arthritis and rheumatism.

[9]  F. Takei,et al.  Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule-1. , 1993, Journal of immunology.

[10]  J. Neefjes,et al.  E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. , 1992, Immunology.

[11]  A. Gearing,et al.  Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. , 1992, Biochemical and biophysical research communications.

[12]  A. Yachi,et al.  Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease. , 1992, Arthritis and rheumatism.

[13]  E. Leroy.  A brief overview of the pathogenesis of scleroderma (systemic sclerosis). , 1992, Annals of the rheumatic diseases.

[14]  J. Becker,et al.  Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. , 1991, Journal of immunology.

[15]  R. Rothlein,et al.  A form of circulating ICAM-1 in human serum. , 1991, Journal of immunology.

[16]  J. Korn.  Immunologic aspects of scleroderma , 1991, Current opinion in rheumatology.

[17]  J. Pearson,et al.  The endothelium: its role in scleroderma. , 1991, Annals of the rheumatic diseases.

[18]  J. Johnson,et al.  Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. , 1991, The Journal of investigative dermatology.

[19]  M. Makgoba,et al.  Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders , 1991, The Lancet.

[20]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[21]  J. Seibold,et al.  Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. , 1990, Arthritis and rheumatism.

[22]  J. Trowsdale,et al.  Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells , 1989, Nature.

[23]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[24]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[25]  Michael Loran Dustin,et al.  Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). , 1986, Journal of immunology.

[26]  Y. Moroi,et al.  Antinuclear antibodies in localized scleroderma. , 1983, Arthritis and rheumatism.

[27]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[28]  J. Seibold,et al.  Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. , 1990, Arthritis and rheumatism.